Research ID
hum0197-v16Release info
Research title
Elucidation of disease state by multi-layered omics analysis
Research overview
- Aims
- Elucidation of disease biology based on trans-omics analysis, GWAS in the Japanese and trans-ethnic populations, Elucidation of the mechanism of COVID-19 severity, Improving the performance of type 2 diabetes polygenic predictions, Elucidation of the genetic architecture of recurrent pregnancy loss, Elucidation of the association between Jomon component in the Japanese population and phenotypes and diseases, Elucidation of the entire HPV integration in HPV-associated Oropharyngeal Cancer, Elucidation of disease state regulation by gene-environment interactions through multi-layered omics analysis, Elucidation of male-specific genetic regulation through multi-layered omics analysis
- Methods
- Metagenome shotgun sequencing, genome-wide association study (GWAS), small RNA-seq and eQTL analyses, whole genome sequencing (WGS), single-cell RNA sequencing, proteomics
- Participants/materials
- Metagenomic data of gut microbiome in the Japanese population (95 + 103 + 227 + 30 + 136 individuals)
Autoimmune pulmonary alveolar proteinosis cases: 198, Control participants: 395
Populations: Biobank Japan (n = 179,000), UK biobank (n = 361,000), and FinnGen (n = 136,000), Phenotypes: 220
141 Japanese individuals
Metagenomic data of gut microbiome in Inflammatory Bowel Disease (35 Ulcerative Colitis and 39 Crohn's disease) and 40 Healthy controls
Intracranial germ cell tumors cases: 133, Control participants: 762
Populations: Biobank Japan (n = 161,801) and UK biobank (n = 377,583), Phenotypes: 9
Peripheral blood mononuclear cell (PBMC) from Japanese population (COVID-19: n = 30 + 43, Healthy controls: n = 31 + 44)
Microbial genome: Metagenome-Assembled Genome (MAG), Viral genome, CRISPR spacers
Metagenomic data of gut microbiome in the Japanese population (88 + 5 individuals) and healthy individuals (n = 73)
BioBank Japan (n=180,215), UK Biobank (n=377,441), and large-scale meta-analysis including the summary statistics of other cohorts [FinnGen, Breast Cancer Association Consortium (BCAC), and Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL)] for breast and prostate cancer (n=648,746 and 482,080), Phenotypes: 15
Hunner-type interstitial cystitis cases: 144, Control participants: 41,516
524 Japanese individuals for gut microbiome-host genome association analysis, 362 Japanese individuals for plasma metabolite-host genome association analysis
The weights of variants existing in the target cohorts, Tohoku Medical Megabank and the second cohort of BBJ, calculated from GWAS results on 27,642 type 2 diabetes cases and 70,242 controls from BioBank Japan and UK Biobank
Recurrent pregnancy loss cases: 1,728, Control participants: 24,315
Autoimmune diseases cases: 2,238, Healthy controls: 2,919
The first cohort of BioBank Japan (n = 171,287)
HPV-associated oropharyngeal cancer cases: 32, Non-HPV-associated oropharyngeal cancer cases: 17, Healthy controls: 2
Neuromyelitis optica spectrum disorders (NMOSD) cases: 240, Control participants: 50,578
Single-cell eQTL summary statistics of 40 immune cell types for Japanese population (COVID-19: n = 88, Healthy controls: n = 146)
Plasma proteomics data from 83 COVID-19 patients and 144 healthy controls of Japanese
Single-cell RNA-sequencing for PBMC from 15 COVID-19 patients and 72 healthy controls of Japanese
Psoriasis cases: 1,415, Control participants: 3,968
Populations: Biobank Japan (n = 166,757) and UK biobank (n = 273,453), Phenotypes: 374
161,026 Japanese males (BBJ: 120,522, JCTF: 3,161, TMM: 26,544, COVC: 888, HERPACC: 6,636, JPHC: 3,275)
Japanese male asthma patients: 3 cases, Japanese male COVID-19 patients: 4 cases
Myasthenia gravis cases: 1,434 (Japan MG Registry), Control participants: 42,913 (BioBank Japan)
401 Moyamoya diseasepatients and 47,255 controls - URL
- N/A
Datasets
The list is the one this version published; each dataset's content is shown as it is now.
| Cart | Dataset ID | Type of data | Analysis method | Access criteria | Date published |
|---|---|---|---|---|---|
| JGAD000290 | Metagenome |
| Controlled-access (Type I) | 2020-09-28 | |
| JGAD000363 | Metagenome |
| Controlled-access (Type I) | 2020-11-27 | |
| JGAD000427 | Metagenome |
| Controlled-access (Type I) | 2021-07-31 | |
| JGAD000532 | Metagenome |
| Controlled-access (Type I) | 2021-12-10 | |
| JGAD000649 | Metagenome |
| Controlled-access (Type I) | 2022-05-20 | |
| JGAD000650 | Metagenome |
| Controlled-access (Type I) | 2022-05-20 | |
| NHA000154 | GWAS for autoimmune pulmonary alveolar proteinosis |
| Unrestricted-access | 2020-11-27 | |
| NHA000162 | GWAS for 215 phenotypes |
| Unrestricted-access | 2021-03-22 | |
| NHA000164 | GWAS for 10 phenotypes |
| Unrestricted-access | 2021-12-21 | |
| NHA000163 | Fine-mapping for 79 phenotypes |
| Unrestricted-access | 2021-12-21 | |
| JGAD000621 | Read count data of miRNA |
| Controlled-access (Type I) | 2022-02-21 | |
| NHA000166 | eQTL data |
| Unrestricted-access | 2022-02-08 | |
| NHA000171 | GWAS for intracranial germ cell tumors |
| Unrestricted-access | 2022-06-10 | |
| NHA000173 | GWAS for 9 phenotypes |
| Unrestricted-access | 2022-06-16 | |
| JGAD000662 | Raw sequencing data of single-cell RNA-seq |
| Controlled-access (Type I) | 2022-07-19 | |
| JGAD000722 | Raw sequencing data of single-cell RNA-seq, clinical data |
| Controlled-access (Type I) | 2023-02-14 | |
| DRA014186 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-06-06 | |
| DRA014188 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-06-06 | |
| DRA014191 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-06-06 | |
| DRA014192 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-06-06 | |
| DRA006684 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2019-02-01 | |
| DRA014184 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-06-06 | |
| NHA000178 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-12-01 | |
| NHA000179 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-12-01 | |
| NHA000177 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-12-01 | |
| JGAD000729 | Metagenome |
| Controlled-access (Type I) | 2023-03-30 | |
| NHA000187 | GWAS for 15 phenotypes |
| Unrestricted-access | 2023-06-06 |
Data provider
- Principal investigator
- Yukinori Okada
- Affiliation
- Department of Statistical Genetics, Osaka University Graduate School of Medicine
Research projects
No research projects.
Grants
| Name | Title | Project number |
|---|---|---|
Precursory Research for Innovative Medical care (PRIME), Advanced Research & Development Programs for Medical Innovation, Japan Agency for Medical Research and Development (AMED) | Crosstalk among microbiome, host, disease, and drug discovery enhanced by statistical genetics |
|
FORCE, Advanced Research & Development Programs for Medical Innovation, Japan Agency for Medical Research and Development (AMED) | Elucidation of disease-specific microbiota and personalized medicine by metagenome-wide association studies |
|
Practical Research Project for Rare / Intractable Diseases, Japan Agency for Medical Research and Development (AMED) | Biology and in silico drug repositioning of pulmonary alveolar proteinosis using trans-layer omics analysis |
|
Practical Research Project for Allergic Diseases and Immunology, Japan Agency for Medical Research and Development (AMED) | Nucleic genome drug discovery for autoimmune diseases through in-silico and patient-oriented screening utilizing large-scale disease genetics |
|
Practical Research Project for Allergic Diseases and Immunology, Japan Agency for Medical Research and Development (AMED) | Genomic prediction medicine of rheumatoid arthritis based on comprehensive immune-omics resources |
|
Platform Program for Promotion of Genome Medicine, Japan Agency for Medical Research and Development (AMED) | Implementation of genomic prediction medicine based on statistical genetics |
|
Platform Program for Promotion of Genome Medicine, Japan Agency for Medical Research and Development (AMED) | Next-generation genomics analyses elucidates biology, personalized medicine, and drug discovery of psoriasis |
|
KAKENHI Grant-in-Aid for Scientific Research (A) | Elucidation of disease biology and tissue specificity by trans-layer omics analysis and whole-genome sequencing |
|
科学研究費助成事業 基盤研究(A) | 統合シークエンス解析による免疫アレルギー疾患ダイナミクスの解明 |
|
Related publications
| Title | DOI | Dataset ID |
|---|---|---|
Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. | ||
Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. | ||
A metagenome-wide association study of gut microbiome in patients with multiple sclerosis revealed novel disease pathology. | ||
Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese | ||
Whole gut virome analysis of 476 Japanese revealed a link between phage and autoimmune disease | ||
Insights from complex trait fine-mapping across diverse populations | ||
Genetic architecture of microRNA expression and its link to complex diseases in the Japanese population. | ||
Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic components. | ||
DOCK2 is involved in the host genetics and biology of severe COVID-19 | ||
Prokaryotic and viral genomes recovered from 787 Japanese gut metagenomes revealed microbial features linked to diets, populations, and diseases | ||
Reconstruction of the personal information from human genome reads in gut metagenome sequencing data | ||
Pan-cancer and cross-population genome-wide association studies dissect shared genetic backgrounds underlying carcinogenesis | ||
Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity | ||
Genome-wide association analysis identifies susceptibility loci within the major histocompatibility complex region for Hunner-type interstitial cystitis | ||
Analysis of gut microbiome, host genetics, and plasma metabolites reveals gut microbiome-host interactions in the Japanese population | ||
Body mass index stratification optimizes polygenic prediction of type 2 diabetes in cross-biobank analyses | ||
Common and rare genetic variants predisposing females to unexplained recurrent pregnancy loss | ||
Blood DNA virome associates with autoimmune diseases and COVID-19 | ||
Genetic legacy of ancient hunter-gatherer Jomon in Japanese populations | ||
Intratumor Heterogeneity of HPV Integration in HPV-associated Head and Neck Cancer | ||
Contribution of germline and somatic mutations to risk of neuromyelitis optica spectrum disorder | ||
Deciphering state-dependent immune features from multi-layer human omics data at single-cell resolution | ||
Whole-genome sequencing reveals rare and structural variants contributing to psoriasis and identifies CERCAM as a risk gene | ||
A Cross-population Compendium of Gene-Environment Interactions | ||
Genetic regulation across germline and somatic variation on the Y chromosome contributes to type 2 diabetes | ||
Integrative GWAS and snRNA-seq Reveal a Mesenchymal-Like Endothelial Signature in Moyamoya Disease | ||
A global atlas of genetic associations of 220 deep phenotypes | ||
Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma |
Controlled access users
| Principal investigator | Affiliation | Country/Region | Research title | Period of data use | Dataset ID |
|---|---|---|---|---|---|
| Ilana Brito | Meinig School of Biomedical Engineering, Cornell University | New York, United States | Comparative metagenomics of lupus patients' microbiomes (Protocol Number IRB0144130) | 2022-05-12 – 2025-01-08 | |
| Yongxin LI | The department of Chemistry, The University of Hong Kong | China | Comparison of gut bacterial diversity and composition in MS/EAE | 2022-09-26 – 2025-06-09 | |
| Michiaki Hamada | Hamada Laboratory, Faculty of Science and Engineering, Waseda University | Japan | Construction of RNA-targeted Drug Discovery Database | 2023-01-05 – 2027-10-31 | |
| Tina Fuchs | Institute for Clinical Chemistry, Medical Faculty Mannheim, Heidelberg University | Germany | Investigating the clonality of VIREM cells in COVID-19 patients | 2024-02-26 – 2025-04-14 | |
| Koichi Matsuda | Clinical genome sequencing, The University of Tokyo | Japan | Disease Cohort Research Network for Disease Marker Exploratory Studies | 2024-06-17 – 2029-03-31 | |
| Yuhei Kirita | Department of Nephrology, Kyoto Prefectural University of Medicine | Japan | Elucidation of the Pathogenesis through Comparative Analysis of Peripheral Blood Gene Expression in IgA Nephropathy and Immune-related Diseases | 2025-07-29 – 2030-03-31 |